Mark Goldsmith
CEOMale0.0Global Dominance: 0.00%
Mark Goldsmith is the CEO of Revolution Medicines, where he has championed the development of daraxonrasib, an experimental drug that targets specific cancer mutations and has shown promise in clinical trials.
Power0
Reach0
Collect
Not in the pool (under ¢1).
Recent news mentions
Mark Goldsmith, CEO of Revolution Medicines, stated that the team is working around the clock to prepare for full approval of the drug.
"לא רואים דברים כאלה": הקהל הריע לתרופה הזוידיעות אחרונות (Yedioth Ahronoth / ynet)·
Israel· 2026-06-01
Israel· 2026-06-01
Mark Goldsmith recalled that most scientists thought their method would destroy normal cells.
Πειραματικό χάπι γεννά ελπίδες για έναν από τους πιο θανατηφόρους καρκίνουςKathimerini·
Greece· 2025-11-06
Greece· 2025-11-06
